News

AmerisourceBergen books $18 billion-plus in Express Scripts business

BY Michael Johnsen

VALLEY FORGE, Pa. — AmerisourceBergen on Tuesday announced that it has signed a three-year agreement to supply approximately $18.5 billion in pharmaceuticals to Express Scripts on an annual basis. The agreement is effective Oct. 1.

“We are honored that Express Scripts has chosen AmerisourceBergen to supply the brand pharmaceuticals it needs for its recently combined mail-order and specialty pharmacy business,” said Steven Collis, AmerisourceBergen president and CEO.

The contract is expected to contribute approximately 23% of ABC’s revenues and about 3% of its earnings per share.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Designer Protein launches reformulated Designer Whey protein powders

BY Michael Johnsen

LOS ANGELES — Designer Protein on Tuesday announced the launch of a reformulated line of Designer Whey protein powders.

"This refresh is the culmination of months spent understanding what is most important to our consumers," stated Grace Jeon, CEO Designer Protein. "Nutrition and wellness are important to keep fueled, but advice on easy integration of sustaining this balanced lifestyle is also important. As a result, we set out to not only deliver without mystery the product benefits our consumers told us were important — taste, health, quality ingredients, convenience and minimal calories — but also deliver on their request for dynamic advice on healthy, active living."

The Designer Whey Protein Powders contain 18 g of whey protein and are fortified with calcium, vitamin D and B vitamins.


Interested in this topic? Sign up for our weekly Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
News

Onglyza improves blood-sugar control in patients with high cardiovascular disease risk

BY Alaric DeArment

PRINCETON, N.J. — A drug made by Bristol-Myers Squibb and AstraZeneca improved several measures of blood-sugar control in Type 2 diabetes patients at high risk of cardiovascular disease, according to results of a late-stage clinical trial announced Monday.

The drug makers announced results of a 1,681-patient phase-3 trial of Onglyza (saxagliptin), in which patients received 5-mg doses of the drug. Results of the 24-week trial showed improved blood-sugar control as measured by HbA1C, fasting plasma glucose and post-meal glucose compared with placebo. Results of the study were presented Monday at the 17th World Congress on Heart Disease in Toronto.

"The population of patients with Type 2 diabetes who are at increased risk for cardiovascular disease was highlighted in a recently issued position statement by the American Diabetes Association and the European Association for the Study of Diabetes," lead study investigator and AstraZeneca global medical affairs manager William Cook said.

The drug, combined with exercise and changes in diet, is already approved for various patients with Type 2 diabetes.


Interested in this topic? Sign up for our weekly DSN Collaborative Care e-newsletter.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?